Cranbury-based Porton Advanced and Dark Horse Consulting Group have signed a Memorandum of Understanding (MOU) to establish a strategic collaboration to accelerate the development and clinical translation of cell and gene therapies globally.
Portion Advanced is a contract development and manufacturing organization (CDMO) specializing in Advanced Therapy Medicinal Products (ATMPs), and Dark Horse is a strategic and operational biotherapeutics consulting firm.
This partnership unites DHCG’s comprehensive regulatory, CMC, nonclinical, clinical, quality & compliance, supply chain, commercial launch, and business analytics consulting capabilities with Porton Advanced’s end-to-end GMP manufacturing infrastructure.
Together, the organizations will offer client companies a cost-effective and rapid pathway into clinical-stage manufacturing, with particular emphasis on enabling Investigator-Initiated Trials (IITs) in China, according to a release.
China has one of the fastest growing and strategically significant markets for advanced therapies, and this collaboration addresses a persistent challenge: navigating the intersection of international regulatory strategy and local manufacturing.
Porton Advanced holds 24 IND clearances across the NMPA and FDA and has successfully supported over 30 IITs to date. DHCG brings deep experience guiding sponsors through the complex regulatory and clinical design requirements that such programs demand.
By combining these capabilities within a formal collaborative framework, DHCG and Porton Advanced will enable sponsors and investigators to move their programs forward more effectively, reducing friction at the manufacturing-regulatory interface that can lead to delays in IIT initiation.
